Gastroenterology and Hepatology from Bed to Bench

Kolodecik T, Shugrue C, Ashat M, Thrower EC. Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol 2014;4:415.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: CA Cancer J Clin. 2014;64:9-29.

Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72.

Gopal S, Sharpless NE. Cancer as a global health priority. JAMA 2021;326:809-10.

Nisar M, Paracha RZ, Adil S, Qureshi SN, Janjua HA. An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer. Front Oncol 2022;12:875188.

Whitcomb DC. Genetics of alcoholic and nonalcoholic pancreatitis. Curr opin Gastroenterol. 2012;28:501-6.

Luu T. Epithelial-mesenchymal transition and its regulation mechanisms in pancreatic cancer. Front Oncol 2021;11:646399.

Walcher L, Kistenmacher A-K, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol 2020;11:1280.

McMenamin ÚC, McCain S, Kunzmann AT. Do smoking and alcohol behaviours influence GI cancer survival? Best Pract Res Clin Gastroenterol 2017;31:569-77.

McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2018;24:4846.

Masoudi S, Sanat ZM, Saleh AM, Nozari N, Ghamarzad N, Pourshams A. Menstrual and reproductive factors and risk of pancreatic cancer in women. Middle East J Dig Dis 2017;9:146.

Yeo TP, editor Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol; 2015: Elsevier.

Zhao Z, Liu W. Pancreatic cancer: a review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat 2020;19:1533033820962117.

Bosetti C, Rosato V, Li D, Silverman D, Petersen G, Bracci P, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 2014;25:2065-72.

Gardner TB, Hessami N, Smith KD, Ripple GH, Barth RJ, Klibansky DA, et al. The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus. Pancreas 2014;43:1018-21.

Raza MH, Gul K, Arshad A, Riaz N, Waheed U, Rauf A, et al. Microbiota in cancer development and treatment. J Cancer Res Clin Oncol 2019;145:49-63.

Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol 2017;101:47-64.

Molina-Montes E, Van Hoogstraten L, Gomez-Rubio P, Löhr M, Sharp L, Molero X, et al. Pancreatic cancer risk in relation to lifetime smoking patterns, tobacco type, and dose–response relationships. Cancer Epidemol Biomarkers Prev 2020;29:1009-18.

Wang Y-T, Gou Y-W, Jin W-W, Xiao M, Fang H-Y. Association between alcohol intake and the risk of pancreatic cancer: a dose–response meta-analysis of cohort studies. BMC cancer 2016;16:1-11.

Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: a systematic review and a series of meta-analyses. EBioMedicine 2015;2:1996-2002.

Downes DP, Daurio NA, McLaren DG, Carrington P, Previs SF, Williams KB. Impact of extracellular fatty acids and oxygen tension on lipid synthesis and assembly in pancreatic cancer cells. ACS Chem Biol 2020;15:1892-900.

Eibl G, Rozengurt E, editors. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin Cancer Biol; 2019: Elsevier.

Koorstra J-BM, Hustinx SR, Offerhaus GJA, Maitra A. Pancreatic carcinogenesis. Pancreatology 2008;8:110-25.

Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, et al. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci 2013;14:19731-62.

Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res 2012;18:4257-65.

Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Prac Res Clin Gastroenterol 2006;20:197-209.

Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS, Sandgren EP. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res 2003;63:2016-9.

Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Deve 2003;17:3112-26.

Bardeesy N, Aguirre AJ, Chu GC, Cheng K-h, Lopez LV, Hezel AF, et al. Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006;103:5947-52.

Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.

Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012;18:4266-76.

Kulkarni AM, Kumar V, Parate S, Lee G, Yoon S, Lee KW. Identification of new KRAS G12D inhibitors through computer-aided drug discovery methods. Int J Mol Sci 2022;23:1309.

Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev 2021:1-17.

Mehra S, Deshpande N, Nagathihalli N. Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress. Cancers 2021;13:4434.

Teixeira AF, Ten Dijke P, Zhu H-J. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front Cell Dev Biol 2020;8:605.

Furukawa T. Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Front Oncol 2015;5:23.

Neiheisel A, Kaur M, Ma N, Havard P, Shenoy AK. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Intl J Cancer 2022;150:727-40.

Ram Makena M, Gatla H, Verlekar D, Sukhavasi S, K. Pandey M, C. Pramanik K. Wnt/β-catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance. Intl J Mol Sci 2019;20:4242.

Gao J, Long B, Wang Z. Role of Notch signaling pathway in pancreatic cancer. Am J Cancer Res. 2017;7:173.

Disis ML, editor Mechanism of action of immunotherapy. Semin Oncol; 2014: Elsevier.

Funamizu N, Lacy CR, Kamada M, Yanaga K, Manome Y. MicroRNA-200b and-301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. Intl J Oncol 2019;54:991-1000.

Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT‐associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun 2021;41:199-217.

Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. RETRACTED: Notch-1 induces epithelial–mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett; 2011.

Liu G, Ji L, Ke M, Ou Z, Tang N, Li Y. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Biomed Pharmacother 2018;106:523-31.

Zhang R, Li M, Zang W, Chen X, Wang Y, Li P, et al. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumor Biol 2014;35:837-44.

Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010;9:3052-64.

Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer cell 2012;21:418-29.

Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009;15:511-9.

Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008;14:5995-6004.

Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 2012;61:172-8.

Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 2008;68:2085-93.

Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012;11:1282-90.

Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-27.

Momi N, Kaur S, Krishn S, Batra SK. Discovering the route from inflammation to pancreatic cancer. Minerva gastroenterol Dietol 2012;58:283.

Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007;14:3629-37.

Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009;69:2400-7.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.

Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006;66:46-51.

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clinical Cancer Res 2006;12:4147-53.

Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 2007;6:532-41.

Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the national cancer database. Cancer 2007;110:738-44.

Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, et al. DNA content and other factors associated with ten‐year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151-9.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 2011;364:1817-25.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.

Zygogianni G, Kyrgias G, Kouvaris J, Antypas C, Skarlatos J, Armpilia C, et al. Intraoperative radiation therapy on pancreatic cancer patients: a review of the literature. Minerva Chir 2011;66:361-9.

Ruano-Ravina A, Ortega RA, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 2008;87:318-25.

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148:349-61.

Burris Hr, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.

Zhu C-P, Shi J, Chen Y-X, Xie W-F, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011;99:108-13.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet 2020;395:2008-20.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015;261:12-7.

Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev 2019;77:1-10.

Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044.

Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG, editors. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Semin Oncol; 2018: Elsevier.

Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, et al. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv264-iv6.

Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013;2:24612.

Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012;18:771-81.

Cerullo V, Koski A, Vähä-Koskela M, Hemminki A. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res 2012;115:265-318.

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9:555-61.

Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.

Heise C, Sampson-Johannes A, Williams A, Mccormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.

Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.

Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res 2010;16:541-53.

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine N, et al. The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther 2011;18:1157-65.

Xu C, Sun Y, Wang Y, Yan Y, Shi Z, Chen L, et al. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett 2012;319:154-63.

Mihaljevic AL, Michalski CW, Friess H, Kleeff J. Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 2010;395:295-308.

Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009;17:614-22.

Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumor Biol 2012;33:1863-70.

Ramírez PJ, Vickers SM, Ono HA, Davydova J, Takayama K, Thompson TC, et al. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg 2008;195:481-90.

Nelson AR, Davydova J, Curiel DT, Yamamoto M. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 2009;100:2181-7.

Huch M, Gros A, José A, González JR, Alemany R, Fillat C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia 2009;11:518-IN6.

Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, et al. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett 2010;294:178-86.

Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, et al. hTERT‐promoter‐dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication‐defective adenovirus vectors in pancreatic cancer cells. Cancer Sci 2010;101:735-42.

Wang H, Li Z-Y, Liu Y, Persson J, Beyer I, Möller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011;17:96-104.

Chu QD, Sun G, Pope M, Luraguiz N, Curiel DT, Kim R, et al. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. Surgery 2012;152:441-8.

Abate-Daga D, Andreu N, Camacho-Sanchez J, Alemany R, Herance R, Millan O, et al. Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One 2011;6:26142.

Eisenberg DP, Carpenter SG, Adusumilli PS, Chan M-K, Hendershott KJ, Yu Z, et al. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery 2010;148:325-34.

Liu B, Robinson M, Han Z, Branston R, English C, Reay P, et al. ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303.

Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 2007;67:9371-9.

Sarinella F, Calistri A, Sette P, Palu G, Parolin C. Oncolysis of pancreatic tumour cells by a γ34. 5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther 2006;13:1080-7.

Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 1999;72:136-41.

Watanabe I, Kasuya H, Nomura N, Shikano T, Shirota T, Kanazumi N, et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer chemother Pharmacol 2008;61:875-82.

Kasuya H, Nishiyama Y, Nomoto S, Goshima F, Takeda S, Watanabe I, et al. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther 2007;14:533-42.

Dai M, Zamarin D, Gao S, Chou T, Gonzalez L, Lin S, et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg 2010;97:1385-94.

Fu X, Tao L, Li M, Fisher WE, Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res 2006;12:3152-7.

Nawa A, Luo C, Zhang L, Ushjima Y, Ishida D, Kamakura M, et al. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr Gene Ther 2008;8:208-21.

Nakao A, Kasuya H, Sahin T, Nomura N, Kanzaki A, Misawa M, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther 2011;18:167-75.

Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011;19:1008-16.

Campadelli‐Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 2011;21:213-26.

Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47.

Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, et al. Phase I/II study of oncolytic HSVGM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010;16:4005-15.

Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9:64-71.

Tysome JR, Briat A, Alusi G, Cao F, Gao D, Yu J, et al. Lister strain of vaccinia virus armed with endostatin–angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 2009;16:1223-33.

Ishizaki H, Manuel ER, Song G-Y, Srivastava T, Sun S, Diamond DJ, et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother 2011;60:99-109.

Hiley CT, Yuan M, Lemoine NR, Wang Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther 2010;17:281-7.

Wennier ST, Liu J, Li S, Rahman MM, Mona M, McFadden G. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther 2012;20:759-68.

Woo Y, Kelly KJ, Stanford MM, Galanis C, Shin Chun Y, Fong Y, et al. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol 2008;15:2329-35.

Petrulio CA, Kaufman HL. Development of the PANVAC™-VF vaccine for pancreatic cancer. Expert Rev Vaccines 2006;5:9-19.

Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 2007;5:1-10.

Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010;21:185-95.

Grekova SP, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, et al. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol Ther 2010;10:1280-9.

Bhat R, Dempe S, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer 2011;128:908-19.

Dempe S, Lavie M, Struyf S, Bhat R, Verbeke H, Paschek S, et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother 2012;61:2113-23.

Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 2010;88:620-5.

Penheiter AR, Wegman TR, Classic KL, Dingli D, Bender CE, Russell SJ, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. Am J Roentgenol 2010;195:341.

Penheiter AR, Dingli D, Bender CE, Russell SJ, Carlson SK. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast‐enhanced computed tomography. J Gene Med 2012;14:590-7.

Carlson SK, Classic KL, Hadac EM, Dingli D, Bender CE, Kemp BJ, et al. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. Am J Roentgenol 2009;192:279.

Bossow S, Grossardt C, Temme A, Leber M, Sawall S, Rieber E, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011;18:598-608.

Himeno Y, Etoh T, Matsumoto T, Ohta M, Nishizono A, Kitano S. Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. Int J Oncol 2005;27:901-6.

Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A, et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003;9:1218-23.

Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic—progress and potential. Mol Cancer Res 2012;10:1514-25.

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin®(Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 2012;20:1998-2003.

Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, et al. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 2013;31:696-706.